ClinicalTrials.gg
CompletedNCT04526106Updated Feb 27, 2026

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

A Phase 1/2 interventional study of RLY-4008 in FGFR2 Amplification, FGFR2 Gene Mutation and FGFR2 Gene Fusion/Rearrangement, sponsored by Elevar Therapeutics. Completed at 48 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Elevar Therapeutics · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
490
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Enrollment
13th of 279
490 · median 44
Started
2020
with 24 others
Phase 1/2
42 of 328
12 open now
Registered
190th of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 13th largest by enrollment of the 279 interventional ones that give a count, is one of 25 that started in 2020, is one of 42 in phase 1/2, and was the 190th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in patients with unresectable or metastatic cholangiocarcinoma (CCA) and other solid tumors. The study consists of 4 parts: a dose escalation (Part 1), a dose expansion (Part 2), and an extension (Part 3) and a rollover (Part 4).

03

Conditions studied

  • FGFR2 Amplification
  • FGFR2 Gene Mutation
  • FGFR2 Gene Fusion/Rearrangement
  • FGFR2 Gene Translocation
  • FGFR2 Gene Activation
  • Intrahepatic Cholangiocarcinoma
  • Cholangiocarcinoma
  • Other Solid Tumors, Adult

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • or cytologically confirmed unresectable or solid tumor
  • Documented FGFR2 gene fusion, mutation, or amplification per local testing of blood and/or tumor
  • Patient must have per v1.1
  • Patient has performance status of 0-1
  • Patient must have disease that is to standard therapy, disease that has not adequately responded to standard therapy, disease for which standard or curative therapy does not exist, or the patient must be intolerant to or have declined standard therapy
  • Part 2 dose expansion patients with Cholangiocarcinoma:

    • Group 1: CCA patients with an FGFR2 fusion previously treated with an FGFRi
    • Group 2: CCA patients with an FGFR2 fusion with prior chemotherapy but not previously treated with an FGFRi
    • Group 6: CCA patients with an FGFR2 fusion with no prior chemotherapy and not previously treated with an FGFRi. Prior /neo-adjuvant treatment completed \>6 months before enrollment is acceptable. Up to 2 cycles of palliative chemotherapy are allowed during screening
    • Group 7: CCA patients with an FGFR2 mutation or amplification and not previously treated with an FGFRi. Note: For Group 7, patients with confirmed diagnosis of unresectable or metastatic CCA with an FGFR2 fusion are not eligible.
  • Part 2 dose expansion patients with other solid tumors (NOT Cholangiocarcinoma):

    • Group 3: Non-CCA patients with an FGFR2 fusion and not previously treated with an FGFRi.
    • Group 4: Non-CCA patients with an FGFR2 amplification and not previously treated with an FGFRi.
    • Group 5: Non-CCA patients with an FGFR2 mutation and not previously treated with an FGFRi
  • Part 3 extension:

    o CCA patients with an FGFR2 fusion with prior chemotherapy but not previously treated with an FGFRi

  • Part 4:

    • Patient is receiving RLY-4008 on RLY-4008-101 study and benefiting from treatment as assessed by the investigator.

Key Exclusion Criteria

  • Parts 1, 2, and 3

    • Ongoing, FGFRi-induced retinal detachment or an ongoing clinically significant corneal or retinal disorder
    • Patient does not have adequate organ function (defined in protocol)
    • Patient has active infection, including (HIV), virus (HBV), and/or virus (HCV) (defined in protocol). Patients with well-controlled HBV are eligible (defined in protocol).
    • corrected using Fridericia\'s formula (QTcF) \> 480 msec or history of prolonged QT syndrome, Torsades de pointes or familial history of prolonged QT syndrome
    • Clinically significant, uncontrolled cardiovascular disease
    • or primary CNS tumor that is associated with progressive neurologic symptoms
  • Part 4:

    • Patient has permanently discontinued treatment with RLY-4008 for any reason before enrolling into Part 4.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
490 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Escalation

    Multiple doses of RLY-4008 for oral administration.

    Drug: RLY-4008

  • Experimental
    Part 2: Dose Expansion

    Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.

    Drug: RLY-4008

  • Experimental
    Part 3: Extension

    Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.

    Drug: RLY-4008

  • Experimental
    Part 4: Rollover

    Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.

    Drug: RLY-4008

Interventions

  • DrugRLY-4008

    RLY-4008 is an oral inhibitor of FGFR2

06

What researchers measure

Primary outcomes

  1. Part 1 and Part 4: Number of patients with adverse events and serious adverse events

    Time frame: Every cycle (4-week cycles) until study discontinuation, approximately 24 months

  2. Part 1: Determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RLY-4008

    Time frame: Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months

  3. Part 2 and Part 3: Objective Response Rate (ORR) assessed by Independent Review Committee per RECIST v1.1

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months

  4. Part 4: Number of patients with dose interruptions

    Time frame: Every 28-day cycle until end of treatment, approximately 24 months.

  5. Part 4: Number of patients with dose reductions

    Time frame: Every 28-day cycle until end of treatment, approximately 24 months.

  6. Part 4: Number of patients with dose discontinuations

    Time frame: Every 28-day cycle until end of treatment, approximately 24 months.

Secondary outcomes

  1. Part 1: FGFR2 gene status in plasma circulating tumor deoxyribonucleic acid (ctDNA) and tumor tissue

    Time frame: Every cycle (4-week cycles) through Cycle 3 and every other cycle thereafter until study discontinuation, approximately 24 months

  2. Part 1: Duration of Response (DOR) assessed by Investigator per RECIST v1.1

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months

  3. Part 1: Disease Control Rate (DCR) as assessed by Investigator per RECIST v1.1

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months

  4. Part 1, Part 2, and Part 3: Objective Response Rate (ORR) as assessed by Investigator per RECIST v1.1

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months

  5. Pharmacokinetic parameters including maximum plasma drug concentration (Cmax)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through Cycle 4 (4-week cycles)

  6. Pharmacokinetic parameters including area under the plasma concentration versus time curve (AUC)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through Cycle 4 (4-week cycles)

  7. Pharmacokinetic parameters including half-life (t1/2)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through Cycle 4 (4-week cycles)

  8. Part 1: Pharmacodynamic parameters including changes in fibroblast growth factor 23 (FGF-23)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every other cycle (4-week cycles) from Cycle 3, approximately 24 months

  9. Part 1: Pharmacodynamic parameters including changes in carcinoembryonic antigen (CEA)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every other cycle (4-week cycles) from Cycle 3, approximately 24 months

  10. Part 1: Pharmacodynamic parameters including changes in cancer antigen 19-9 (CA 19-9)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every other cycle (4-week cycles) from Cycle 3, approximately 24 months

  11. Part 2 and Part 3: Duration of response (DOR) assessed by Investigator and Independent Review Committee per RECIST v1.1

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months

  12. Part 2 and Part 3: Progression-free survival (PFS) assessed by Investigator and Independent Review Committee per RECIST v1.1

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months

  13. Part 2 and Part 3: Disease control rate (DCR) assessed by Investigator and Independent Review Committee per RECIST v1.1

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months

  14. Part 2 and Part 3:Overall survival (OS)

    Time frame: Up to approximately 36 months.

  15. Part 2 and Part 3:Change from baseline in quality of life as assessed by EORTC QLQ-C30

    Time frame: Approximately every 4 weeks during treatment, approximately 24 months

  16. Part 2 and Part 3:Dose intensity

    Time frame: Every 28-day cycle until end of treatment, approximately 24 months.

  17. Part 2 and Part 3: Number of patients with dose interruptions

    Time frame: Every 28-day cycle until end of treatment, approximately 24 months.

  18. Part 2 and Part 3: Number of patients with dose reductions

    Time frame: Every 28-day cycle until end of treatment, approximately 24 months.

  19. Part 2 and Part 3: Number of patients with dose discontinuations

    Time frame: Every 28-day cycle until end of treatment, approximately 24 months.

  20. Part 2 and Part 3: Correlation between FGFR2 genotype by central tissue assessment and antitumor response, as measured by ORR

    Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months

07

Study locations

48 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Taussig Cancer Institute Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Texas Oncology
    Dallas, Texas 75246, United States
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute, University of Utah
    Salt Lake City, Utah 84112, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • St. Vincent's Hosptial Sydney
    Darlinghurst, 2010, Australia
  • Linear Clinical Research Ltd
    Nedlands, 6009, Australia
  • Icon Cancer Care South Brisbane
    South Brisbane, 4101, Australia
  • Institut Bergonie
    Bordeaux, 33076, France
  • Centre Georges François Leclerc
    Dijon, 21079, France
  • Centre Leon Berard
    Lyon, 69373, France
  • Gustave Roussy Cancer Campus
    Paris, 94805, France
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • LMU Klinikum, Campus Grosshadern
    Munich, 81377, Germany
  • Queen Mary Hospital
    Hong Kong, 999077, Hong Kong
  • Istituto Europeo di Oncologia
    Milan, 20141, Italy
  • Netherlands Cancer institute
    Amsterdam, 1066 CX, Netherlands
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
  • National Cancer Center Singapore
    Singapore, 169610, Singapore
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • START Barcelona-Hospital HM Nou Delfos
    Barcelona, 08023, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Fundación Jiménez Díaz- START MADRID
    Madrid, 28040, Spain
  • Hospital Universitario HM Sanchinarro-START MADRID-CIOCC
    Madrid, 28050, Spain
  • Clinica de Universidad de Navarra
    Pamplona, 31008, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Karolinska University Hospital
    Stockholm, 17176, Sweden
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • Guy's Hospital
    London, SE1 9RT, United Kingdom
  • Sarah Cannon Research Institute UK
    London, W1G 6AD, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, W1T 7HA, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
08

References and documents

Publications

  • Ellis H, Balasooriya ER, Varkaris A, Hajian B, Wan J, Shekhar M, Gritti I, Vijay V, Albertelli L, Piot S, Lau K, Kehlmann A, Chevalier N, Nugent FW, Zhen Y, Silveira VS, Sellers WR, Corcoran RB, Juric D, Bardeesy N. Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib. Ann Oncol. 2026 Jun;37(6):798-812. doi: 10.1016/j.annonc.2026.01.004. Epub 2026 Jan 20. PubMed 41571046 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Sep 2025, 60 months.

Of 40 phase 1/2 interventional studies under Cholangiocarcinoma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 77. This study's 60 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2020
First posted
Aug 25, 2020
StartActual
Sep 2, 2020
Primary completionActual
Sep 5, 2025
CompletionActual
Sep 5, 2025
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04526106
Lead sponsor
Elevar Therapeutics
Responsible party
Sponsor
First posted
Aug 25, 2020
Start date
Sep 2, 2020
Primary completion
Sep 5, 2025
Completion
Sep 5, 2025
Last update
Feb 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion